<DOC>
	<DOC>NCT01224769</DOC>
	<brief_summary>This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.</brief_summary>
	<brief_title>Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>patients with relapsed or refractory chronic lymphoproliferative disorders salvage treatment with bendamustine +/ rituximab age â‰¥ 18 years previous treatment with bendamustine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>